Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
B-cell prolymphocytic leukemia pathophysiology
Introduction
Overview
Overview
B-cell prolymphocytic leukemia arises from mature B-cells, which are hematologic white cells that are normally involved in the in the humoral immunity component of the adaptive immune system by secreting antibodies.
Pathophysiology
Pathophysiology
Markers
- B-cell prolymphocytic leukemia cells are positive for B cell markers such as CD19, CD20, CD22.[1]
- CD23 is negative but CD5 is expressed in one third tumor cells population.[2][3]
- Another case was described as CD45+, CD19+, CD20+, CD5+, HLA-DR+, CD10-, CD23+/-, CD38+ and FMC7[4]
- Tumor cells express surface IgM proteins.
Microscopic pathology
- The originating cell line for B-cell prolymphocytic leukemia is a mature B-cells and are medium sized cells.
- More than 50 percent of the circulating cells in the peripheral blood are prolymphocytes.
- The nucleus is typically round or oval, and the cytoplasm is usually moderately abundant.
- Leukemic cells can be found in peripheral blood, lymph nodes, bone marrow, spleen, liver, and skin.[5]
References
References
- ↑ Yamamoto K, Hamaguchi H, Nagata K, Shibuya H, Takeuchi H (April 1998). “Splenic irradiation for prolymphocytic leukemia: is it preferable as an initial treatment or not?”. Jpn. J. Clin. Oncol. 28 (4): 267–9. doi:10.1093/jjco/28.4.267. PMID 9657013.
- ↑ “Pathology”. Archived from the original on 7 February 2009. Retrieved 2009-01-31.
- ↑ Yi S, Li Z, Wang H, Liu W, Lyu R, Yu Z, Qi J, Qiu L (April 2014). “[The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders]”. Zhonghua Xue Ye Xue Za Zhi (in Chinese). 35 (4): 337–41. doi:10.3760/cma.j.issn.0253-2727.2014.04.019. PMID 24759024.
- ↑ Crisostomo RH, Fernandez JA, Caceres W (May 2007). “Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia”. Leuk. Res. 31 (5): 699–701. doi:10.1016/j.leukres.2006.06.010. PMID 16997373.
- ↑ Stone RM (April 1990). “Prolymphocytic leukemia”. Hematol. Oncol. Clin. North Am. 4 (2): 457–71. PMID 2182602.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2],Carlos A Lopez, M.D. [3]